Texas Permanent School Fund Invests $859,000 in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Texas Permanent School Fund acquired a new position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWDGet Rating) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 74,497 shares of the biotechnology company’s stock, valued at approximately $859,000.

Other hedge funds have also recently made changes to their positions in the company. Aaron Wealth Advisors LLC bought a new stake in shares of Ironwood Pharmaceuticals in the 1st quarter worth approximately $290,000. Banque Cantonale Vaudoise bought a new stake in shares of Ironwood Pharmaceuticals in the 2nd quarter worth approximately $58,000. Lazard Asset Management LLC bought a new stake in shares of Ironwood Pharmaceuticals in the 1st quarter worth approximately $78,000. Quantbot Technologies LP bought a new stake in shares of Ironwood Pharmaceuticals in the 1st quarter worth approximately $109,000. Finally, Pinnacle Wealth Planning Services Inc. bought a new stake in shares of Ironwood Pharmaceuticals in the 2nd quarter worth approximately $123,000.

Ironwood Pharmaceuticals Stock Up 2.7 %

Shares of NASDAQ IRWD opened at $11.64 on Monday. The company has a quick ratio of 25.78, a current ratio of 25.78 and a debt-to-equity ratio of 0.67. Ironwood Pharmaceuticals, Inc. has a 52 week low of $9.73 and a 52 week high of $12.95. The firm’s fifty day moving average is $10.74 and its 200 day moving average is $11.26. The company has a market cap of $1.79 billion, a price-to-earnings ratio of 12.25 and a beta of 0.99.

Analysts Set New Price Targets

IRWD has been the topic of several analyst reports. Capital One Financial initiated coverage on shares of Ironwood Pharmaceuticals in a research note on Friday, September 2nd. They issued an “overweight” rating and a $15.00 target price on the stock. Wells Fargo & Company lifted their target price on shares of Ironwood Pharmaceuticals from $12.00 to $13.00 and gave the stock an “equal weight” rating in a research note on Tuesday, August 16th. Finally, StockNews.com initiated coverage on shares of Ironwood Pharmaceuticals in a research note on Wednesday, October 12th. They issued a “buy” rating on the stock. One equities research analyst has rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $14.67.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, CEO Thomas A. Mccourt sold 18,899 shares of the business’s stock in a transaction on Monday, October 3rd. The shares were sold at an average price of $10.41, for a total transaction of $196,738.59. Following the transaction, the chief executive officer now directly owns 712,440 shares of the company’s stock, valued at approximately $7,416,500.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 13.10% of the company’s stock.

Ironwood Pharmaceuticals Profile

(Get Rating)

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union.

Read More

Want to see what other hedge funds are holding IRWD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWDGet Rating).

Institutional Ownership by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.